A metabolite-augmented FIB-4 machine learning panel achieves superior liver fibrosis staging in chronic liver disease

Clinical Snapshot

Key Findings

• P Value: Not reported in abstract

• Effect Size: CHB: 96.3% rule-out sensitivity, 85.4% rule-in specificity for significant fibrosis; MASLD: 93.9% rule-out sensitivity, 90.2% rule-in specificity

• Primary Outcome: Diagnostic accuracy for liver fibrosis staging

• Nnt Or Sensitivity: Sensitivity 96.3% (CHB) and 93.9% (MASLD) for significant fibrosis; Specificity >97.9% for advanced disease

• Confidence Interval: Not reported in abstract

Clinical Application

Requires metabolomics capability and machine learning infrastructure, potentially limiting widespread implementation Could reduce reliance on FibroScan and liver biopsy in Australian hepatology services, though TGA approval and PBS listing would be required for metabolite testing Patients with chronic hepatitis B or metabolic dysfunction-associated liver disease requiring fibrosis assessment

Abstract

Accurate, non-invasive liver fibrosis detection is essential for chronic liver disease management, particularly with rising metabolic dysfunction-associated liver disease (MASLD) and chronic hepatitis B (CHB). While the Fibrosis-4 (FIB-4) index is widely used, its performance for advanced fibrosis is limited. We develop Met-FIB using metabolomics and machine learning, integrating FIB-4 parameters (age, aspartate aminotransferase, alanine aminotransferase, and platelet count) with tyrosine and taurocholic acid identified in a CHB discovery cohort (n = 3,251). Validation includes one CHB cohort (n = 729) and two MASLD cohorts (n = 149, n = 155). Met-FIB outperforms FIB-4, FibroScan, and other serum markers across all fibrosis stages. In CHB, Met-FIB achieves 96.3% rule-out sensitivity and 85.4% rule-in specificity for significant fibrosis, with rule-in specificity reaching 98.6% and 98.8% for advanced fibrosis and cirrhosis. In MASLD, corresponding values are 93.9% and 90.2% for significant fibrosis, with >97.9% specificity for late-stage disease. Met-FIB demonstrates clinical utility for non-invasive fibrosis staging across diverse etiologies.